Oxford Asset Management’s Coherus Oncology CHRS Stock Holding History

Oxford Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-61,615	Closed	-$1.11M	–	416
2019 Q4	$1.11M	Buy	+61,615	New	+$1.14M	0.03%	802
2019 Q2	–	Sell	-29,232	Closed	-$399K	–	1728
2019 Q1	$399K	Buy	+29,232	New	+$390K	0.01%	1315
2016 Q3	–	Sell	-43,157	Closed	-$729K	–	777
2016 Q2	$729K	Buy	+43,157	New	+$810K	0.02%	538

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Oxford Asset Management's CHRS Position: Q1 2020 in Review

Oxford Asset Management sold out of Coherus Oncology (CHRS) in Q1 2020, closing a stake of 61,615 shares — an estimated $1.11M sold.

Oxford Asset Management first reported a position in CHRS in Q2 2016 and held it in 3 quarters. The position peaked at $1.11M in Q4 2019. 186 funds tracked by Wall St. Rank hold CHRS as of Q1 2020.

Oxford Asset Management reported no remaining Coherus Oncology position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 61,615 Coherus Oncology shares in Q1 2020, an estimated $1.11M.
Oxford Asset Management first reported a position in Coherus Oncology in Q2 2016 and held it in 3 quarters.
Oxford Asset Management's Coherus Oncology position peaked at $1.11M in Q4 2019.
186 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.